Etoposidum [INN-Latin] en es it fr

Etoposidum [INN-Latin] Brand names, Etoposidum [INN-Latin] Analogs

Etoposidum [INN-Latin] Brand Names Mixture

  • No information avaliable

Etoposidum [INN-Latin] Chemical_Formula


Etoposidum [INN-Latin] RX_link

Etoposidum [INN-Latin] fda sheet,%20VP-16

Etoposidum [INN-Latin] msds (material safety sheet)

Etoposidum_[INN-Latin] MSDS

Etoposidum [INN-Latin] Synthesis Reference

No information avaliable

Etoposidum [INN-Latin] Molecular Weight

588.557 g/mol

Etoposidum [INN-Latin] Melting Point

236-251 oC

Etoposidum [INN-Latin] H2O Solubility

58.7 mg/L

Etoposidum [INN-Latin] State


Etoposidum [INN-Latin] LogP


Etoposidum [INN-Latin] Dosage Forms

Solution; Capsule; Liquid

Etoposidum [INN-Latin] Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Etoposidum [INN-Latin] Pharmacology

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

Etoposidum [INN-Latin] Absorption

Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50%.

Etoposidum [INN-Latin] side effects and Toxicity

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

Etoposidum [INN-Latin] Patient Information

Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. It is advised to drink lots of fluids after treatment to prevent damage to the bladder and kidneys, typically 1.5 to 3.5 litres of water on the day of treatment and for several days after.

Etoposidum [INN-Latin] Organisms Affected

Humans and other mammals